AstraZeneca seems to have dodged the problems besetting other developers of oral selective oestrogen receptor degrader (SERD) drugs with a phase 2 win for its candidate camizestrant in a ph
Johnson & Johnson has secured another regulatory approval for its BCMAxCD3 bispecific antibody for multiple myeloma – Tecvayli – adding to the wide range of therapies available for the
AstraZeneca's lengthy and turbulent development of CTLA4 inhibitor tremelimumab has at least led to a regulatory approval as part of a combination therapy for advanced liver cancer.
Lung, breast, and non-prostate genitourinary (NGU) cancer treatments were the most exciting tracks due to the march towards personalised medicine and expanded immunotherapy options.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
